Trojan Bio
Harnessing viral specific immunity for fighting cancer
- Headquarters
- Yavne
- Employees
- 1–10
- Founded
- 2021
- Business Model
- B2B
- Website
- trojan-bio.com
- Total Funding
- $904K
About
Trojan Bio is developing a novel class of therapeutic antibodies for the treatment of solid tumors. The company's Trojan antibody platform integrates viral peptides into antibody structures, enabling them to penetrate tumor microenvironments and activate the immune system from within—harnessing antiviral immunity to fight cancer. Trojan Bio won the Biomed Israel 2025 Startup Competition and is backed by Peregrine Ventures.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account